Simplicity Solutions LLC Sells 1,062 Shares of Moderna, Inc. (NASDAQ:MRNA)

Simplicity Solutions LLC lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 24.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,349 shares of the company’s stock after selling 1,062 shares during the quarter. Simplicity Solutions LLC’s holdings in Moderna were worth $333,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRNA. Norges Bank bought a new stake in Moderna during the 4th quarter valued at $628,359,000. Renaissance Technologies LLC increased its stake in Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Morgan Stanley increased its stake in Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after acquiring an additional 517,683 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the transaction, the insider now owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,954 shares of company stock worth $11,533,976. Insiders own 15.70% of the company’s stock.

Moderna Stock Down 0.6 %

Shares of Moderna stock opened at $101.41 on Friday. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $144.43. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The company’s 50-day moving average price is $100.63 and its 200-day moving average price is $93.64.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period in the prior year, the firm posted $3.61 earnings per share. The company’s revenue for the quarter was down 44.9% on a year-over-year basis. As a group, research analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on MRNA shares. Canaccord Genuity Group upped their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research note on Tuesday, January 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research note on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.